Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors

NCT02219724 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02219724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02219724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2014
Completion date
August 18, 2019
Enrollment
174 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms